Global Erythropoietin Drugs Market: Segmental Highlights and Table of Content (2017-2025)

By Shashiipawar    11 / Dec / 2017    In Category Healthcare

img

Global Erythropoietin Drugs Market: High Rate of Cancer Diagnosis Improves Uptake, says TMR

According to the research report, the global erythropoietin drugs market is expected to be worth US$19,379.2 mn by the end of 2025 as it surges at CAGR of 7.5% from 2017 to 2025. Out of the various applications of erythropoietin drugs, cancer is expected to be the highest revenue contributor.

The Global Erythropoietin Drugs Market is segmented on the basis of Drug Class, Drug Type, Drug Application and Geography.

On the basis of drug class, the market has been segmented into epoetin alfa, epoetin beta, darbepoetin alfa, others. Epoetin alfa was the dominant segment in 2016. It is anticipated to remain dominant in the forecast period, in terms of revenues. Epoetin alfa is usually related with cancer chemotherapy and chronic renal failure. Rising the prevalence of cancer worldwide according to National institute of cancer, 1,685,210 new cases of cancer estimated in year 2016. On the basis of drug application, the market has been segmented into cancer, renal disease, hematology, neurology, others (surgery, wound healing, etc.). Cancer was the dominant segment in 2016. It is anticipated to remain dominant in the forecast period, in terms of revenues, owing to the factors such as increasing prevalence of chronic diseases globally.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1856

Based on drug type, the market has been segmented into biologics and biosimilars. The biologic erythropoietin drugs dominated the market in 2016 and are anticipated to remain dominant in the forecast period. This segment is anticipated to grow at a high CAGR during the forecast period owing to long drug exclusivity period, which provides manufacturers a high return on investment (ROI). On the basis of distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2016 and is anticipated to remain the dominant segment in terms of revenues in the forecast period. The online pharmacy segment is anticipated to grow at a significant high CAGR during the forecast period, owing to the factors such as increasing reach of online pharmacy to the customers, rising the internet facilities globally, and other services such as cost containment offered by online pharmacy.

Geographically, the market has been segmented into five regions, including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America was the dominant region in terms of revenues in 2016 and is anticipated to remain dominant in the forecast period. The growth in the region can be attributed to the increasing approvals of erythropoietin drugs, government incentives offered for research on chronic disease such as research and development grants, drug exclusivity, tax credit and fee waivers, among others.

Request to Browse Full Table of Content, figure and Tables @ https://www.transparencymarketresearch.com/report-toc/1856

Summary of Table of Content

1. Preface
2. Assumptions and Research Methodology
3. Executive Summary
4. Market Overview
5. Global Erythropoietin Drugs Market Analysis, by Drug Class
6. Global Erythropoietin Drugs Market Analysis, by Drug Type
7. Global Erythropoietin Drugs Market Analysis, by Drug Application
8. Global Erythropoietin Drugs Market Analysis, by Region
9. North America Erythropoietin Drugs Market Analysis
10. Europe Erythropoietin Drugs Market Analysis
11. Asia Pacific Erythropoietin Drugs Market Analysis
12. Asia Pacific Erythropoietin Drugs Market Analysis
13. Middle East & Africa Erythropoietin Drugs Market Analysis